Evidence map›Paper›PMID 34696837›Full record

ArticleThe Enzymes2021

Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs.

Kieran Maheden, Brendan Todd, Calvin J Gordon, Egor P Tchesnokov, Matthias Götte

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Enzymes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kieran MahedenDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada; School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada.
Brendan ToddDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.
Calvin J GordonDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.
Egor P TchesnokovDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.
Matthias GötteDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada; Li Ka Shing Institute of Virology at University of Alberta, Edmonton, AB, Canada. Electronic address: gotte@ualberta.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of viral infections remains challenging, in particular in the face of emerging pathogens. Broad-spectrum antiviral drugs could potentially be used as a first line of defense. The RNA-dependent RNA polymerase (RdRp) of RNA viruses serves as a logical target for drug discovery and development efforts. Herein we discuss compounds that target RdRp of poliovirus, hepatitis C virus, influenza viruses, respiratory syncytial virus, and the growing data on coronaviruses. We focus on nucleotide analogs and mechanisms of action and resistance.

Indexed as

Antiviral AgentsNucleotidesRNA-Dependent RNA PolymeraseViral Replicase Complex ProteinsVirusesVirus ReplicationAntiviral AgentsNucleotidesRNA-Dependent RNA PolymeraseViral Replicase Complex ProteinsAntiviralsCoronavirusHepatitis C virusInfluenza virusNucleotide analogsPoliovirusRespiratory syncytial virusRNA virusViral polymerase inhibitor

Identifiers

PMID34696837
PMCPMC8517576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.